Stockreport

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Matinas Biopharma Holdings, Inc.  (MTNB) 
NASDAQ:AMEX Investor Relations: ir.matinasbiopharma.com
PDF BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on deli [Read more]